biotech
biotech Articles
Here 24/7 Wall St. includes a calendar of a few of the biggest companies expecting clinical trial and FDA updates in the month of December.
Published:
24/7 Wall St. has reviewed the top biotech companies, without focusing on speculative companies. The November 15 short interest data has been compared with the previous report, and short interest in...
Published:
ChemoCentryx shares more than tripled on Tuesday after the firm, in conjunction with Vifor Fresenius Medical Care Renal Pharma, announced positive topline data from its late-stage trial of avacopan...
Published:
Global Blood Therapeutics shares jumped on Tuesday after the firm announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval for Oxbryta (voxelotor) tablets for the...
Published:
Medicines Co shares shot up on Monday after it was reported that Novartis will be acquiring the firm. The transaction was unanimously approved by the boards of directors of both companies.
Published:
Aquestive Therapeutics shares jumped on Monday after the firm announced that its treatment of amyotrophic lateral sclerosis (ALS), Exservan, received early-action approval from the U.S. Food and Drug...
Published:
Iovance Bio announced results from a subgroup analysis of metastatic melanoma patients in its Phase 2 study of lifileucel.
Published:
ProQR Therapeutics shares jumped early on Thursday after the firm announced that it received an approval from the FDA for its autosomal dominant retinitis pigmentosa drug.
Published:
Aravive shares skyrocketed on Wednesday after the firm announced early-stage data for its ovarian cancer treatment.
Published:
Kiniksa Pharma shares jumped on Wednesday after the firm announced that the FDA granted Breakthrough Therapy designation for rilonacept for the treatment of recurrent pericarditis.
Published:
Karuna Therapeutics shares skyrocketed on Monday after the firm announced mid-stage results from its schizophrenia treatment. Now shares are on the move again after Karuna said that it would be...
Published:
Myovant Sciences shares more than doubled on Tuesday after the firm announced results from its Phase 3 Hero study of relugolix for prostate cancer.
Published:
Medicines shares shot up on Tuesday after it was reported that Novartis might be eyeing this company as its newest acquisition.
Published:
On top of the potential game-changer for schizophrenia patients, some Karuna Therapeutics investors just experienced the same euphoria as holding a winning lottery ticket.
Published:
There is a huge risk-reward factor in emerging pharmaceutical and biotech companies that happen to have all their eggs in just one basket. That's the case of resTORbio.
Published:
Last Updated: